Gefitinib as the first-line treatment in metastatic adenocarcinoma patients with EGFR mutation-positive: A single-centre retrospective cohort study in Hospital Pulau Pinang, Malaysia

被引：0
|
作者：
Appava, Sumithra [1 ]
Subramaniam, Deepa Priya Naidu [1 ]
Muneswarao, Jaya [2 ]
Tan, Ai Lian [3 ]
Pereirasamy, Lalitha [1 ]
Goon, Ai Khiang [1 ]
Muthukumaru, Umadevi [1 ]
Ali, Irfhan Ali Hyder [1 ]
机构：
[1] Hosp Pulau Pinang, Resp Dept, George Town, Malaysia
[2] Hosp Pulau Pinang, Dept Pharm, George Town, Malaysia
[3] Hosp Pulau Pinang, Dept Oncol, George Town, Malaysia
来源：
RESPIROLOGY | 2023年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AP08-338
引用
收藏
页码：318 / 319
页数：2
相关论文
共 50 条
  • [1] Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review
    Koehler, Jens
    Schuler, Martin
    ONKOLOGIE, 2013, 36 (09): : 510 - 518
  • [2] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] GEFITINIB/CHEMOTHERAPY VERSUS CHEMOTHERAPY IN EGFR MUTATION-POSITIVE NSCLC AFTER PROGRESSION ON FIRST-LINE GEFITINIB: IMPRESS STUDY DESIGN
    Wu, Y. -L.
    Mok, T.
    Soria, J. -C.
    Nakagawa, K.
    Zhang, X.
    Miao, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 23 - 23
  • [4] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
    Douillard, J-Y
    Ostoros, G.
    Cobo, M.
    Ciuleanu, T.
    McCormack, R.
    Webster, A.
    Milenkova, T.
    BRITISH JOURNAL OF CANCER, 2014, 110 (01) : 55 - 62
  • [5] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
    J-Y Douillard
    G Ostoros
    M Cobo
    T Ciuleanu
    R McCormack
    A Webster
    T Milenkova
    British Journal of Cancer, 2014, 110 : 55 - 62
  • [6] Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)
    Wang, J.
    Cheng, Y.
    Wu, Y.
    An, T.
    Gao, H.
    Wang, K.
    Zhou, Q.
    Hu, Y.
    Song, Y.
    Ding, C.
    Peng, F.
    Liang, L.
    Hu, Y.
    Huang, C.
    Zhou, C.
    Shi, Y.
    Zhang, L.
    Ye, X.
    Sun, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1844 - S1844
  • [7] Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study
    Abdullah, Matin Mellor
    Bhat, Amit
    Mohamed, Ahmad Kamal
    Ching, Foo Yoke
    Ahmed, Nida
    Gantotti, Sandeep
    ONCOLOGY LETTERS, 2016, 11 (04) : 2757 - 2762
  • [8] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
  • [9] First-line chemotherapy for metastatic breast cancer in patients ≥75 years: A retrospective single-centre analysis
    Debled, Marc
    Madranges, Nicolas
    Mertens, Cecile
    Durand, Michel
    Brouste, Veronique
    Brain, Etienne
    Mauriac, Louis
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 80 (01) : 171 - 179
  • [10] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
12345